CYP19A1 and breast carcinoma: It results in better outcome by augmenting the yield of mature oocytes and embryos in aromatase inhibitor cycles, and furthermore it reduces the post-trigger estradiol exposure and ovarian hyperstimulation syndrome (OHSS) risks in women with breast cancer, too (31).